ALDX 4.88 (+0.41%)
US01438T1060BiotechnologyBiotechnology

Aldeyra Therapeutics (ALDX) Stock Highlights

4.88 | +0.41%
2024-12-21 05:53:58
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The companys product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Statistics

Range Today
4.79 5.02
Volume Today 430.4K
Range 1 Year
2.71 6.55
Volume 1 Year 129M
Range 3 Year
1.42 11.97
Volume 3 Year 686.61M
Range 10 Year
1.42 16.7
Volume 10 Year 1.4B

Highlights

Market Capitalization 328.01M (small)
Floating Shares 43.22M
Current Price 4.88
Price To Earnings -8.39
Price To Book 3.86
Earnings Per Share -0.64
Payout Ratio 0%

Performance

Latest +0.41%
1 Month -0.2%
3 Months -18.94%
6 Months +35.93%
1 Year +46.11%
3 Years -29.58%
5 Years -15.86%
10 Years -37.91%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.